Orphazyme

$12.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.28 (+2.23%) As of 3:46 PM UTC today

Why Robinhood?

You can buy or sell Orphazyme and other stocks, options, and ETFs commission-free!

About ORPH

Orphazyme A/S engages in development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Mørkeberg Hinsby, Marja Jäättela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark. The listed name for ORPH is Orphazyme A/S American Depositary Shares.

CEO
Anders Fink Vadsholt
Employees
86
Headquarters
Copenhagen, Capital Region
Founded
2009
Market Cap
431.85M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
5.85K
High Today
$12.72
Low Today
$12.70
Open Price
$12.72
Volume
300.00
52 Week High
$13.98
52 Week Low
$8.89

You May Also Like

FYC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure